InsiderTrades.com logo
The “Next Bitcoin”? 10 CENT Crypto Set to Explode
From True Market Insiders   |   Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024
Spyridon Papapetropoulos net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Spyridon Papapetropoulos Biography and Net Worth

Director of Adamas Pharmaceuticals
Dr. Papapetropoulos is a board-certified neurologist with over 20 years of academic and industry experience in neurology and neurosciences. He has deep experience in neurodegenerative diseases and movement disorders and in bringing multiple neurological therapies to market. Since leaving academia, Dr. Papapetropoulos has held R&D and scientific leadership roles at leading neurological companies including Acadia, Teva, Pfizer, Allergan, and Biogen. He is currently Chief Medical Officer for Vigil Neuro. Dr. Papapetropoulos was trained in Queen’s Square, London, UK and holds appointments as Consultant with Massachusetts General Hospital and Voluntary Professor of Neurology with the University of Miami, Miller School of Medicine.

What is Spyridon Papapetropoulos' net worth?

The estimated net worth of Spyridon Papapetropoulos is at least $131,314.50 as of March 11th, 2021. Dr. Papapetropoulos owns 15,975 shares of Adamas Pharmaceuticals stock worth more than $131,315 as of April 26th. This net worth estimate does not reflect any other assets that Dr. Papapetropoulos may own. Learn More about Spyridon Papapetropoulos' net worth.

How do I contact Spyridon Papapetropoulos?

The corporate mailing address for Dr. Papapetropoulos and other Adamas Pharmaceuticals executives is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. Adamas Pharmaceuticals can also be reached via phone at (510) 450-3500 and via email at [email protected]. Learn More on Spyridon Papapetropoulos' contact information.

Has Spyridon Papapetropoulos been buying or selling shares of Adamas Pharmaceuticals?

Spyridon Papapetropoulos has not been actively trading shares of Adamas Pharmaceuticals during the past quarter. Most recently, on Thursday, March 11th, Spyridon Papapetropoulos bought 5,975 shares of Adamas Pharmaceuticals stock. The stock was acquired at an average cost of $5.06 per share, with a total value of $30,233.50. Following the completion of the transaction, the director now directly owns 15,975 shares of the company's stock, valued at $80,833.50. Learn More on Spyridon Papapetropoulos' trading history.

Who are Adamas Pharmaceuticals' active insiders?

Adamas Pharmaceuticals' insider roster includes Martha Demski (Director), Spyridon Papapetropoulos (Director), Christopher Prentiss (CFO), and Vijay Shreedhar (Insider). Learn More on Adamas Pharmaceuticals' active insiders.

Spyridon Papapetropoulos Insider Trading History at Adamas Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/11/2021Buy5,975$5.06$30,233.5015,975View SEC Filing Icon  
See Full Table

Spyridon Papapetropoulos Buying and Selling Activity at Adamas Pharmaceuticals

This chart shows Spyridon Papapetropoulos's buying and selling at Adamas Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Adamas Pharmaceuticals Company Overview

Adamas Pharmaceuticals logo
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Read More

Today's Range

Now: $8.22
Low: $8.22
High: $8.22

50 Day Range

MA: $8.17
Low: $7.97
High: $8.23

2 Week Range

Now: $8.22
Low: $4.02
High: $9.15

Volume

N/A

Average Volume

692,487 shs

Market Capitalization

$376.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.82
The “Next Bitcoin”? 10 CENT Crypto Set to Explode
From True Market Insiders   |   Ad
The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…
Click For My #1 FREE Crypto for 2024